Skip to main content
OpenTrials
Completed

NCT Number: NCT01888744

Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist

The aim of our study is to define the optimal ovarian stimulation protocol concerning PGD and for this reason we plan a randomized controlled trial (RCT) comparing gonadotropin-releasing hormone (GnRH) agonist protocol versus GnRH antagonist protocol. The follicle stimulating hormone (FSH) preparation in both arms will be highly purified FSH (Menopur®).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Reproductive Endocrinology Fertility Optimal Stimulation Protocol

Age range

18 year–39 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Centre for Reproductive Medicine

Brussels, 1090, Belgium

About this study

Patients will be randomized at the outpatient clinic in two groups.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ≤ 39 years the day of oocyte retrieval
  • BMI ≤ 29
  • cycle rank 1
  • menstrual cycle 25-36 days
  • PGD or preimplantation genetic screening (PGS) requested
  • ICSI
  • Single embryo transfer (SET) on day 5

Exclusion criteria

  • Polycystic Ovary Syndrome (PCOS) (according Rotterdam criteria)
  • Hormonal disturbances
  • Endometriosis grade III and IV

Treatment and study plan

GnRH agonist

Drug

Other names: Suprefact nasal spray

GnRh antagonist

Drug

Other names: Orgalutran or Cetrotide

HP-hMG

Drug

Other names: Menopur

Human Chorionic Gonadotropin

Drug

induction of final oocyte maturation

Other names: Pregnyl

Progesterone

Drug

Other names: Utrogestan vaginal tablets

Primary outcomes

  1. Number of day 3 embryos for biopsy available

    Time frame: up to 6 weeks

Secondary outcomes

  1. Number of mature cumulus-oocyte complexes

    Time frame: up to 6 weeks

  2. clinical pregnancy rate

    Time frame: up to 9 months

Sponsors and collaborators

Lead sponsor

Universitair Ziekenhuis Brussel

Other

Registry information

Official study title

The Effect of the Type of Ovarian Stimulation Protocol on PGD Results: a Prospective Randomised Trial

Acronym: Avanti

Important dates

Study start
2010
Primary completion
2013
Study completion
2013
First posted
Jun 28, 2013
Registry last updated
Jun 28, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.